Repurposing Licensed Drugs for Use Against Alzheimer’s Disease
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Alzheimer's Disease"
DOI: 10.3233/jad-210080
Abstract: Substantial evidence, composed of drug mechanisms of action, in vivo testing, and epidemiological data, exists to support clinical testing of FDA-approved drugs for repurposing to the treatment of Alzheimer’s disease (AD). Licensed compound investigation can… read more here.
Keywords: repurposing licensed; disease repurposing; alzheimer disease; licensed drugs ... See more keywords